The S&P/ASX 200 Index (ASX: XJO) has suffered heavy losses over the past month. 

Since August 6th, Australia’s benchmark index has fallen more than 6%. 

Despite the pain for many investors’ portfolios, there are several strong value options. 

Yesterday, these three ASX shares hit 52-week lows:

• GQG Partners Inc (ASX: GQG)
• IVE Group Ltd (ASX: IGL)
• Generation Development Group Ltd (ASX: GDG). 

For value investors, these ASX shares could be enticing opportunities. 

GQG Partners

GQG Partners is a global boutique asset management company focused on active equity portfolios. It offers investment advisory and portfolio management services for investors across three continents.

In the last 12 months, its share price has fallen 38%. 

At the time of writing, it is trading at a 52-week low of $1.05. 

However, it now sits well below where many experts believe is fair value. 

Late last month, Morgans placed an accumulate rating and price target of $1.52. 

The near-term operating environment remains difficult for GQG; however, we think it’s hard not to see long-term value in the franchise at current levels, trading on ~7x FY1 PE.

This indicates an upside potential of almost 45%. 

While this capital gain upside is already enticing, this ASX stock also offers a strong dividend yield. 

At the time of writing, it offers a yield of over 10%, providing investors with passive income and potential capital gains. 

IVE Group

IVE provides communication solutions. Its services include creative services, personalised communications, print production, retail display, promotional merchandising, third-party sourcing, logistics and fulfilment, and managed solutions.

In the last 12 months, its share price has fallen 13%, and now sits at a 52-week low of $2.34. 

However, analysts’ forecasts via TradingView have an average one year target of $3.20. 

This indicates an upside potential of 36%. 

-It also recently posted some healthy full-year results, suggesting the underlying businesses remain sound. 

It also offers a dividend yield of over 7%. 

Generation Development Group

Generation Development Group is a diversified financial services company focused on investment and retirement products.

Its share price has fallen more than 57% in the last 12 months and is now hovering near a 52-week low of $2.92. 

The current price sits well below broker targets. 

TradingView analyst data has an average 12-month price target of $5.39 on this ASX stock. 

This indicates 84% upside from current levels. 

The post 3 ASX shares trading at 52-week lows that could be outstanding value plays  appeared first on The Motley Fool Australia.

More reading

• Brokers tip these 3 ASX shares to climb between 50% and 122% in the next 12 months
• GQG Partners shares in focus after August 2026 FUM update
• Buy, hold, sell: Generation Development, Fletcher Building, Saluda Medical shares
• How much passive income can I earn off a $550,000 superannuation balance?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Generation Development Group and Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The value of investment assets you can own while still qualifying for the age pension is about to get a boost. From 20 September, the upper thresholds are rising and if you’re sitting close to the old limit, this change could be the difference between missing out and pocketing a payment.

The lift comes from indexation adjustments, made twice a year to keep pace with inflation. Here’s exactly what’s changing.

Who qualifies, and when

If you were born on or after 1 January 1957, you become eligible for the pension at age 67 — retired or not.

Two tests decide your payment of the age pension: an assets test and an income test. Both get new guardrails on 20 September. This article zeroes in on the assets test.

What counts and what doesn’t

Your home is excluded entirely from the assets test. Renters get more breathing room too, with higher thresholds to compensate for not owning property.

What does count: superannuation, ASX shares, bonds, investment properties, and cash.

This round of indexation only lifts the upper thresholds, the point where your part-pension cuts out completely.

New limits if you own your home

Single homeowners with assets under $333,000 get the full pension. Between $333,001 and $745,750 (up from $733,500), you’ll get a part-payment.

Couple homeowners with assets under $499,000 get the full pension. Between $499,001 and $1,121,000 (up from $1,102,500), it’s a part-payment.

New limits if you rent

Single renters with assets under $600,000 get the full payment. Between $600,001 and $1,012,750 (up from $1,000,500), you’ll get a part-payment.

Couple renters with assets under $766,000 get the full payment. Between $766,001 and $1,388,000 (up from $1,369,500), it’s a part-pension.

How much will you actually get?

Payments are rising too. Single pensioners get an extra $36.80 per fortnight from 20 September, lifting the full pension to $1,237.70 per fortnight.

Couples get an extra $27.80 per partner, per fortnight, bringing the full pension to $933 per partner, per fortnight.

Even a tiny pension is worth claiming

Here’s the part too many retirees overlook: even if your assets sit right near the upper limit and you only qualify for a few dollars a fortnight, apply anyway.

Why? Because that part-pension unlocks the Pensioner Concession Card (PCC), and the PCC is worth far more than the payment itself. It can shave thousands of dollars a year off everyday living costs in retirement, from healthcare to utilities to transport.

Foolish takeaway

Indexation changes like this rarely make headlines, but they can genuinely shift whether you qualify for age pension or how much.

If your asset position is anywhere near these thresholds, it’s worth checking your eligibility again after 20 September. A payment that looked out of reach in August might be back on the table in September.

The post Want the age pension? Here’s the new asset limit you can’t exceed appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• The ASX 200 is finally rising. Is the sell-off running out of steam?
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today
• ASX 200 drops again as selling continues

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

4DMedical vs Telix Pharmaceuticals shares: which health innovator wins?

If you’re weighing up a buy between 4DMedical Ltd (ASX: 4DX) and Telix Pharmaceuticals Ltd (ASX: TLX), you’re comparing two ambitious Australian medical technology companies. Both are at the forefront of healthcare innovation, but their financial profiles and recent growth stories offer very different investment prospects. Let’s dig in to see how these two stack up.

The case for 4DMedical

4DMedical is breaking new ground in respiratory imaging. Its flagship CT:VQ software turns CT scans into detailed lung maps, giving doctors advanced tools for diagnosing diseases like pulmonary embolism and emphysema. The tech’s already in use at top US hospitals like Mayo Clinic and Stanford, with a recent European expansion thanks to its acquisition of Contextflow.

Looking at the numbers, 4DMedical carries a sizeable market cap of $2.07 billion but has yet to become profitable, posting negative earnings per share of -0.405. There’s no dividend on offer, and no price/earnings (P/E) ratio available yet; this signals it’s still firmly in growth mode. The year-to-date return sits at -14.5%, indicating a tough recent run for shareholders. This makes 4DX more of a high-risk, high-potential play, especially for those backing new technology looking to disrupt established medical imaging markets.

The case for Telix Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage biotech pushing the boundaries of cancer diagnostics and treatment. Its main product, Illuccix, has approvals from regulators including the TGA, FDA and Health Canada, making it a global force in prostate cancer imaging. Beyond Illuccix, Telix is running more than 20 clinical trials worldwide, chasing breakthroughs in cancer types ranging from kidney to brain to bone marrow.

Telix stands out for having already turned the corner into profitability. Its market cap dwarfs 4DMedical’s at $6.03 billion. Earnings per share are positive (0.099), which is rare for an ASX biotech this size. The company trades on an eye-watering P/E ratio of 118.40—sky-high, but not unusual for fast-growing pharmaceutical businesses. Like 4DMedical, Telix pays no dividend, pouring resources back into growth. But the real highlight is a stellar year-to-date share price return of 45.89%, signalling momentum.

Valuation comparison

Here’s a side-by-side look at the major valuation and fundamental metrics:

Metric	4DMedical (4DX)	Telix Pharmaceuticals (TLX)
Market Cap	$2.07 billion	$6.03 billion
P/E Ratio	N/A	118.40
Earnings per Share	-0.405	0.099
Dividend Yield	0.00%	0.00%
Year to Date Return	-14.50%	45.89%

There’s a clear gap in scale and financial maturity. Telix is both far larger by market cap and actually generating earnings, whereas 4DMedical is still burning through capital to develop its market. Neither pays a dividend, so both are pure growth plays.

Recent share price performance

Share prices can be volatile in the health tech sector, but the difference here is striking. As of the latest data (mid-September 2026), 4DMedical shares sit at $3.44, having dropped 14.5% year to date. Its weekly moves have often swung several percent either way, showing volatility without a clear upward momentum.

Telix, meanwhile, is on a tear. As of 15 September 2026, shares closed at $17.75 and are up a hefty 45.89% for the year. The stock has seen sharp daily moves—like an 8.63% gain on one recent day—but the overall trend has been strongly positive. Telix’s growth story is, at least so far, being rewarded by the market.

Which is the better buy?

Weighing up these two, my pick would be Telix Pharmaceuticals. The company has global regulatory runs on the board, it’s already doing solid revenue, and it’s delivered real profit. Yes, it does trade on a huge earnings multiple, but I’d see that as justified given the momentum: 45% year-to-date gains, and more than 20 clinical trials in the pipeline.

4DMedical clearly has exciting technology and major growth aspirations, but as of now, it’s loss-making and suffering negative share price performance.

In short: if I’m backing an Aussie health innovator today, I’d go with Telix.

The post 4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown appeared first on The Motley Fool Australia.

More reading

• Are Telix shares a buy after its big US FDA news?
• These 2 ASX healthcare shares just jumped up to 15%. Here’s why
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial draft. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.